

RNS Number : 6082T  
Intl. Biotechnology Trust PLC  
09 June 2009

## INTERNATIONAL BIOTECHNOLOGY TRUST PLC

### Portfolio Update

The Board of International Biotechnology Trust plc (the "Company") notes the following development within the quoted portfolio.

On Monday, 8 June 2009 portfolio company Micromet, Inc. (NASDAQ: MITI), announced that one of its drugs, Blinatumomab, had achieved its primary endpoint in a Phase II study for Acute Lymphoblastic Leukaemia Patients.

As at close of business on Friday, 5 June 2009, the Company's investment in MITI represented £6.8m or 7.3% of the Company's net asset value ("NAV") at a closing price of \$4.61 per share. At close of business on Monday, 9 June 2009, the share price was \$4.97 per share - a 7.8% increase in value - which represented £7.3m or 7.9% of the Company's NAV at close of business yesterday.

### Enquiries:

Kate Bingham/David Pinniger

Telephone: 020 7412 7070

SV Life Sciences Managers LLP

Investment Manager

Rachael Nelson

Telephone: 020 7410 3132

BNP Paribas Secretarial Services Limited

Company Secretary

9 June 2009

